Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Mar 5, 2024, after the close
10-K filed Mar 5, 2024, 65 days after period end · 0001558370-24-002475
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $35.79M | $51.28M | $20.41M | $18.45M |
| Net Income | $737.00K | $1.40M |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$22.64M |
| -$19.24M |
| EPS Diluted | — | — | — | -$0.11 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
